Resistance to Beta Lactam Antibiotics of Pseudomonas aeruginosa Isolated in Community Infections within HIV Infected Persons in Lomé-Togo

Majesté Ihou Wateba, Kanyni Ekoue-Kouvahey, Abago Balaka, Komivi Tsatsu, Ousseni Tidjani

Department of Infectious Diseases and Pneumology, CHU Sylvanus Olympio, Lomé, Togo.
Department of Internal Medicine, CHU Sylvanus Olympio, Lomé, Togo.
Medical Center of NGO VISA, Lomé, Togo.

DOI: 10.4236/wja.2014.41010                

Abstract

Objective: Describe resistance to beta lactam antibiotics of Pseudomonas aeruginosa in community infection within HIV-1 infected persons. Methods: We have studied prospectively from June 15th to December 31st 2013 inthe Clinic Hotel-Dieu and NGO VISA of Lomé, adult HIV-1 infected patients under anti retroviral therapy combining tenofovir, lamivudine and efavirenz for at least one year. The technique of agar diffusion susceptibility using discs of Ticarcillin + clavulanic acid is used to study the β-lactamase production. The diagnosis of species was performed by the chloroform test and the test for sensitivity to kanamycin and colistin. Results: Thirty five strains of Pseudomonas aeruginosa were obtained. The T-lymphocytes CD4 mediane was 575 cells/mm3 of blood. Urine represented 15 cases, skin abscesses 11 cases, externa suppurate otitis 7 cases and vaginal swab for 2 cases. The phenotypes were: wild phenotypes 23 cases (65.7%), resistant phenotypes 12 cases. Among resistant phenotypes, 4 were complex phenotype; 5 were ESBL phenotypes; 2 were hyper productive cephalosporinases phenotypes and 1 was a specific phenotype with impermeability to imipenem. Conclusion: The acquisition of resistance of Pseudomonas aeruginosa to beta lactam antibiotics in community infections among HIV-1 infected person incentives controls and promotes the rational use of antibiotics.

Keywords

HIV-1; Pseudomonas aeruginosa; Resistance Phenotypes; Beta Lactam Antibiotic

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Liu, P.V. and Mercer, C.B. (1963) Growth, and Virulence of Toxigenicity Pseudomonas Aeruginosa. The Journal of Hygiene, 61, 485-491. http://dx.doi.org/10.1017/S0022172400021100
[2]	Feldman, M., Bryan, R., Rajan, S., Scheffler, L., Brunnert, S., Tang, H. and Prince, A. (1998) Role of Flagella in Pathogenesis of Pseudomonas aeruginosa Pulmonary Infection. Infection and Immunity, 66, 43-51.
[3]	Bignandi, A. (2005) Vente illicite du médicament. Thèse de Pharmacie, Lomé, 34-39.
[4]	MS/DGS/DES (2006) Répertoire des établissements privés de santé au Togo. 23-25.
[5]	Jeannat, K. and Plesiat, P. (2005) Therapeutic Implication of Antibiotic Resistance in Pseudomonas. Lettre de l’infectiologue, 7.
[6]	Navon-Venezia, S., Ben Ami, R. and Carmeli, Y. (2005) Update on Pseudomonas aeruginosa and Acinetobacter baumanii Infections in the Healthcare Setting. Current Opinion in Infectious Diseases, 18, 306-313. http://dx.doi.org/10.1097/01.qco.0000171920.44809.f0
[7]	Faure, K., Kipnis, E. and Gueri, B. (2008) Prise en charge des pneumonies à Pseudomonas aeruginosa. Rev Tun Infectiol., 2, 1-8.
[8]	Ait El Kadi, M., Aghrouch, M., Seffar, M., Elharti, J., Bouklouze, A., Cherrah, Y., et al. (2006) Prévalence des souches d'Acinetobacter baumannii et de Pseudomonas aeruginosa résistantes à l'imipénème par production de métallo-β-lactamases. Med Mal Infect., 36, 386-389. http://dx.doi.org/10.1016/j.medmal.2006.05.003